1. Anti-infection
  2. HIV

Ebselen (Synonyms: SPI-1005; PZ-51; CCG-39161)

Cat. No.: HY-13750 Purity: 99.89%
Data Sheet SDS Handling Instructions

Ebselen is a small-molecule capsid Inhibitor of HIV-1 replication.

For research use only. We do not sell to patients.
Ebselen Chemical Structure

Ebselen Chemical Structure

CAS No. : 60940-34-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $70 In-stock
50 mg $140 In-stock
100 mg $240 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Ebselen is a small-molecule capsid Inhibitor of HIV-1 replication. Target: Ebselen is an organoselenium compound, as an inhibitor of HIV-1 capsid CTD dimerization. Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. [1] Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties. Ebselen is an inhibitor of inositol monophosphatase (IMPase). Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain. [2]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT03013400 University of Oxford|Stanley Medical Research Institute|Sound Pharmaceuticals, Incorporated Bipolar Disorder|Bipolar Disorder, Manic June 30, 2017 Phase 2
NCT00762671 Brigham and Women's Hospital Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus May 1999 Phase 2|Phase 3
NCT02819856 Sound Pharmaceuticals, Incorporated|Medical University of South Carolina|Cystic Fibrosis Foundation Therapeutics Ototoxicity May 2017 Phase 1|Phase 2
NCT02603081 Sound Pharmaceuticals, Incorporated Meniere's Disease December 2015 Phase 1|Phase 2
NCT01452607 Sound Pharmaceuticals, Incorporated Hearing Loss|Cancer May 2006 Phase 1
NCT02779192 Sound Pharmaceuticals, Incorporated Noise Induced Hearing Loss September 2016 Phase 2
NCT01444846 Sound Pharmaceuticals, Incorporated|University of Florida Temporary Auditory Threshold Shift September 2011 Phase 2
NCT01451853 Sound Pharmaceuticals, Incorporated|VA Puget Sound Health Care System Lung Cancer|Head and Neck Cancer|Hearing Loss|Ototoxicity|Tinnitus|Neuropathy August 2016 Phase 2
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 3.6472 mL 18.2362 mL 36.4724 mL
5 mM 0.7294 mL 3.6472 mL 7.2945 mL
10 mM 0.3647 mL 1.8236 mL 3.6472 mL
Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.89%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: